Mer­ck looks to ditch the nee­dles with its next-gen oral PC­SK9 in­hibitor for high cho­les­terol

Af­ter win­ning ap­proval about six years ago, the first wave of PC­SK9 in­hibitors large­ly failed to muster the block­buster sales an­a­lysts had pre­dict­ed. Now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.